I have found a news statement:
Chiome Bioscience Inc. (Tokyo:4583) will use its Autonomously Diversifying Library (ADLib) technology to generate mAbs for GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). GSK has an option to develop compounds generated under the deal. Details were not disclosed. Chiome's ADLib technology generates antibodies through gene conversion in a chicken B cell line. Chiome was off Y34 to Y1,014 on Thursday.
Well, let's make deconstruction! Let's take a look on the key word and messages in this brief article.
- Autonomously Diversifying Library (ADLib) technology – it sounds sexy – if I were an investor I would buy this idea just because it sounds extremely scientific!
- to generate mAbs – monoclonal antibodies is one of the hot issues in targeted drug development of a last decade, therefore it is worth to invest in this project!
- to generate mAbs for GlaxoSmithKline plc – well, you see? GlaxoSmithKline plc already made a decision to be interested in the coming products! Big Pharma will buy all the stuff that will be produced!How would I comment this? Well, good luck with monoclonal antibodies! It is perfect deal to consume the money and not to develop any useful product – the ideal simulation, and nobody will suspect the intentions! Everything looks scientific and respectable in accordance to our expectations. The jack-pot is growing!
No comments:
Post a Comment